Scientists have had a whirlwind of activity in 2015, a year that turned out to be especially prolific for medicine. We’ve witnessed dazzling discoveries, tech‑driven breakthroughs, and clever new twists on established tools. Below you’ll find the 10 biggest medical headlines of 2015 that promise to leave a lasting imprint on health around the globe.
10 Biggest Medical Highlights of 2015
10 Discovery Of Teixobactin
Back in 2014, the World Health Organization sounded the alarm that humanity was slipping into a “post‑antibiotic era,” and the warning proved all too prescient. The last brand‑new antibiotic to reach clinical use dated back to 1987, leaving a three‑decade void as drug‑resistant bugs multiplied. Fast‑forward to 2015, when a team of researchers unveiled a discovery that many have hailed as a true game‑changer.
The investigators uncovered an entirely new class of antimicrobial agents, tallying 25 fresh compounds, with one standout named teixobactin. Unlike traditional antibiotics, teixobactin attacks bacteria by halting the construction of their cell walls, a strategy that makes it extraordinarily difficult for microbes to evolve resistance. Early experiments have shown the drug to be lethal against MRSA and several tuberculosis‑causing organisms.
Equally striking was the novel cultivation technique the scientists employed to harvest these molecules. They engineered a “subterranean hotel,” a series of isolated chambers each housing a single bacterial cell, allowing each microbe to grow in its own private room.
These miniature hotels are then buried in soil, creating a fertile environment where previously uncultivable bacteria can flourish and spew out new antibiotics. Promising mouse trials with teixobactin have paved the way for human studies, slated to commence around 2017.
9 Doctors Grow Vocal Cords From Scratch
The frontier of tissue regeneration took a bold leap in 2015 when a group at the University of Wisconsin succeeded in growing human vocal cords entirely from scratch. Led by Dr. Nathan Welham, the team bio‑engineered a tissue that mimics the delicate mucosal lining of the vocal folds – the tiny flaps that vibrate in the larynx to produce speech.
Cells harvested from five volunteers were cultured for two weeks before being affixed to excised larynges equipped with artificial windpipes. The engineered cords emitted a distinct “eeee‑like” tone, reminiscent of a robotic kazoo, which researchers argue matches the sound a solitary human cord would generate in isolation.
Crucially, when these lab‑grown cords were implanted into mice engineered to possess human‑like immune systems, the tissue was not rejected. The scientists believe the grafts enjoy a degree of immunoprivilege, meaning they can coexist with the host’s immune defenses without triggering an attack.
8 Cancer Drug Might Help Parkinson’s Sufferers
Nilotinib – sold under the brand name Tasigna and already approved for treating certain leukemias – was repurposed in a daring 2015 clinical trial at Georgetown University Medical Center to see if it could ease Parkinson’s disease symptoms. The drug appeared to boost cognition, motor function, and a suite of non‑motor abilities in participants.
Dr. Fernando Pagan, one of the trial’s lead investigators, suggested that nilotinib could be the first therapy capable of actually reversing the cognitive and motor decline typical of neurodegenerative disorders like Parkinson’s.
The six‑month study enrolled twelve patients, each receiving gradually increasing doses of the medication. Eleven completed the trial, and ten reported noticeable clinical improvements, ranging from sharper thinking to smoother movement.
While safety was the primary endpoint – confirming that low‑dose nilotinib could be tolerated without serious side effects – the small sample size and lack of a placebo control mean further research is essential before the drug can be considered a standard Parkinson’s treatment.
7 World’s First 3‑D‑Printed Rib Cage
3‑D printing surged into the medical spotlight again in 2015 when surgeons at Spain’s Salamanca University Hospital performed the world’s inaugural rib‑cage transplant using a custom‑made titanium prosthesis. The patient’s chest wall sarcoma required removal of a sizable portion of his ribs and sternum.
Traditional titanium implants consist of multiple interlocking pieces that can loosen over time and often fail to match an individual’s unique skeletal geometry. To overcome these hurdles, the team fed high‑resolution CT scans into a $1.3 million Arcam printer, which fabricated a single, patient‑specific titanium structure encompassing both sternum and rib sections.
The operation proceeded without a hitch, and the recipient recovered fully, demonstrating that personalized 3‑D‑printed bone implants can safely replace large skeletal sections and potentially reduce post‑operative complications.
6 Skin Cells Turned Into Brain Cells
Scientists at the Salk Institute in La Jolla, California, unveiled a clever method for coaxing ordinary skin cells to become bona fide brain cells, opening fresh avenues for studying neurodegenerative disease. By reprogramming skin samples, the researchers generated “aged” neurons that faithfully recapitulate the hallmarks of older brain tissue.
This breakthrough sidesteps the reliance on animal models, which often fall short of capturing human‑specific disease mechanisms. The team also demonstrated that stem‑cell‑derived neurons can be coaxed to produce serotonin, a neurotransmitter implicated in autism, schizophrenia, and depression, whereas earlier lab‑grown neurons predominantly secreted glutamate.
Having a reliable source of human serotonin‑producing neurons promises to accelerate research into mental‑health disorders and may eventually aid in drug discovery tailored to the human brain’s chemistry.
5 Male Birth Control Pill
Researchers at Osaka University’s Institute for Microbial Diseases in Japan have uncovered a potential pathway toward a reversible male birth‑control pill. By repurposing two immunosuppressive drugs—tacrolimus and cyclosporine A—originally used to prevent organ‑rejection, they aimed to temporarily halt sperm function.
Both compounds inhibit calcineurin, an enzyme that also appears in sperm‑specific proteins PPP3R2 and PPP3CC. In mouse experiments, animals lacking PPP3CC displayed infertility, suggesting that disabling this protein compromises the sperm’s ability to penetrate an egg.
When normal male mice were treated with the two drugs for just four to five days, they became temporarily infertile, yet their fertility rebounded within a week after stopping the medication. Because calcineurin isn’t a hormone, the approach is unlikely to dampen libido.
Although these findings are encouraging, translating a male pill from mice to humans remains a steep climb; roughly 80 % of rodent studies fail to predict human outcomes. Nonetheless, the fact that the drugs are already approved for human use offers a glimmer of hope for future contraceptive options.
4 DNA Printing
The rise of 3‑D printing gave birth to a novel industry dedicated to “printing” DNA, though the term is a bit of a misnomer. Cambrian Genomics’ CEO likens the process to high‑tech spell‑checking: millions of DNA fragments sit on tiny beads, a computer scans the library, selects the needed pieces, and a laser fires to deposit the chosen strands onto a collection tray, assembling the desired sequence.
While the technology sparks excitement about future DIY organism design, it also raises ethical eyebrows concerning misuse. Presently, the primary customers are pharmaceutical firms and research labs that need custom DNA for experiments or drug development.
At the Karolinska Institute in Sweden, scientists pushed the envelope further by arranging DNA strands into the shape of a bunny—a technique dubbed DNA origami. Though it looks like party trickery, the method holds promise for creating sturdier drug‑delivery vehicles that can survive longer inside the body.
3 Nanobots Work In Living Creature
Early 2015 marked a milestone for nanorobotics when a University of California, San Diego team demonstrated that microscopic robots could perform a task inside a living animal. The nanobots were implanted into laboratory mice, where they navigated to the stomach and released tiny gold flakes.
Post‑procedure examinations revealed no damage to the stomach lining, confirming the bots’ safety. Moreover, the gold payload remained in the stomach longer than when simply ingested, hinting at a more efficient drug‑delivery platform.
The bots’ propulsion stems from zinc‑based motors that generate hydrogen bubbles upon contact with stomach acid, propelling the devices forward. Eventually, the zinc dissolves, leaving no trace. This breakthrough paves the way for future nanomachines that could seek out and treat disease at the cellular level.
2 Injectable Brain Nano Implant
Harvard engineers unveiled a flexible, injectable brain‑mesh that could revolutionize treatment for a spectrum of neurological conditions, from neurodegenerative disease to paralysis. The device consists of a scaffold woven from conductive polymer threads, each intersection housing a tiny transistor or nanoscale electrode.
Designed to mimic the softness of brain tissue, the mesh is primarily empty space, allowing neurons to grow around it without being displaced. Early animal trials involved implanting the 16‑component mesh into mice, where it successfully recorded and stimulated individual neuronal activity.
While the technology remains in the pre‑clinical stage, the promising results suggest a future where such implants could monitor brain health, deliver targeted stimulation, and even encourage neuronal regeneration.
1 THC‑Producing Yeast
Marijuana’s therapeutic compounds have long been harvested from the plant itself, but a team at Germany’s Technical University of Dortmund engineered a strain of yeast capable of synthesizing THC, the primary psychoactive molecule. The researchers also hinted at a yeast line that can produce cannabidiol, another medically valuable cannabinoid.
Traditional cultivation remains the most efficient way to obtain THC, with modern strains yielding up to 30 % of their dry weight as the compound. The new yeast, however, starts from precursor molecules rather than simple sugars, resulting in modest yields per batch.
Future work aims to fine‑tune the metabolic pathways so the yeast can generate larger quantities of THC, providing a scalable, plant‑free source for pharmaceutical research and potentially easing regulatory hurdles in regions where cultivating cannabis is restricted.